Scientific article

Nouveautés dans la prise en charge de l’infection à cytomégalovirus chez les patients transplantés

Published inRevue médicale suisse, vol. 19, no. 822, p. 726-730
Publication date2023-04-12

Cytomegalovirus (CMV) infection remains a significant infectious complication after transplantation. In this article, we summarize the recent advances in the management of CMV infection in solid-organ and hematopoietic stem-cell transplant recipients. Firstly, recent trials have better delineated the indications for the preventive strategies available, namely antiviral prophylaxis and the preemptive approach. Secondly, the antiviral armamentarium has been expanded with the advent of less toxic oral drugs that are available for antiviral prophylaxis and for therapy of refractory/resistant CMV infection. Finally, increasing evidence suggests that cell-mediated immune assays can be used in routine care for individualizing the prevention strategies against CMV.

  • Humans
  • Organ Transplantation / adverse effects
  • Transplant Recipients
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / etiology
  • Cytomegalovirus Infections / prevention & control
  • Antiviral Agents / therapeutic use
  • Hematopoietic Stem Cell Transplantation / adverse effects
Citation (ISO format)
NEOFYTOS, Dionysios, VAN DELDEN, Christian, MANUEL, Oriol. Nouveautés dans la prise en charge de l’infection à cytomégalovirus chez les patients transplantés. In: Revue médicale suisse, 2023, vol. 19, n° 822, p. 726–730. doi: 10.53738/REVMED.2023.19.822.726
Main files (1)
Article (Published version)
accessLevelRestrictedaccessLevelPublic 10/13/2024
ISSN of the journal1660-9379

Technical informations

Creation09/27/2023 11:04:52 AM
First validation01/10/2024 4:40:26 PM
Update time01/10/2024 4:40:26 PM
Status update01/10/2024 4:40:26 PM
Last indexation05/06/2024 5:44:03 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack